Entresto sales are expected to increase following its inclusion in major US insurance formularies.
By Louisa Joseph, Analyst
17 March 2016
Despite slow initial uptake, US sales of Entresto are expected to increase following the drug’s inclusion in major insurance formularies.
Datamonitor Healthcare surveyed 210 cardiologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to calculate the CHF treatment population and to gain an understanding of current and future prescribing patterns in CHF.
Novartis reported sluggish sales of Entresto in the second half of 2015, reaching only $21m. This poor performance was driven primarily by limited formulary access in the US, as most major formularies take around six months to evaluate a new product. Around 65% of the patients eligible to receive Entresto are covered by the Medicare Part D formulary, which did not provide any coverage of the drug until October 2015.
With Entresto now included on Medicare Part D, as well as a number of major commercial formularies, Datamonitor Healthcare expects sales of the drug to increase throughout the upcoming years. Additionally, Novartis has discussed plans for a “pay-for-performance” reimbursement model, which could facilitate reimbursement of the drug in the US, as well as the more cost-conservative European markets.
Datamonitor Healthcare’s CHF: forecast covers the expected impact of newly branded therapies on the highly genericized CHF market, as well as a detailed look at the current CHF pipeline.
Register for a free demo to find out more information on our latest chronic heart failure report >>>
If you are a current subscriber you can view our Chronic Heart Failure forecast here
Posted in Latest Research.